4//SEC Filing
ROBBINS LARRY 4
Accession 0000905148-25-001466
CIK 0000064803other
Filed
May 5, 8:00 PM ET
Accepted
May 6, 4:15 PM ET
Size
16.9 KB
Accession
0000905148-25-001466
Insider Transaction Report
Form 4
ROBBINS LAWRENCE M
Director
Transactions
- Sale
Common Stock
2025-05-02$69.66/sh−373,776$26,035,592→ 9,670,731 total(indirect: Held by Glenview Investment Funds) - Sale
Common Stock
2025-05-05$67.99/sh−96,999$6,595,272→ 8,346,799 total(indirect: Held by Glenview Investment Funds) - Sale
Common Stock
2025-05-02$67.39/sh−1,679,736$113,190,186→ 10,267,063 total(indirect: Held by Glenview Investment Funds) - Sale
Common Stock
2025-05-02$68.38/sh−222,556$15,218,980→ 10,044,507 total(indirect: Held by Glenview Investment Funds) - Sale
Common Stock
2025-05-05$67.37/sh−1,226,933$82,654,673→ 8,443,798 total(indirect: Held by Glenview Investment Funds) - Sale
Common Stock
2025-05-06$66.67/sh−150,000$10,000,710→ 8,196,799 total(indirect: Held by Glenview Investment Funds)
Footnotes (9)
- [F1]These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (collectively, the "Glenview Investment Funds").
- [F2]This price reflects the weighted average price for open-market sales of Shares on May 2, 2025 within a $1.00 range. The actual prices for these transactions range from $67.08 to $68.07, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
- [F3]The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein.
- [F4]The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CEO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares.
- [F5]This price reflects the weighted average price for open-market sales of Shares on May 2, 2025 within a $1.00 range. The actual prices for these transactions range from $68.08 to $69.0764, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
- [F6]This price reflects the weighted average price for open-market sales of Shares on May 2, 2025 within a $1.00 range. The actual prices for these transactions range from $69.0817 to $70.035, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
- [F7]This price reflects the weighted average price for open-market sales of Shares on May 5, 2025 within a $1.00 range. The actual prices for these transactions range from $66.925 to $67.92, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
- [F8]This price reflects the weighted average price for open-market sales of Shares on May 5, 2025 within a $1.00 range. The actual prices for these transactions range from $67.925 to $68.26, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
- [F9]This price reflects the weighted average price for open-market sales of Shares on May 6, 2025 within a $1.00 range. The actual prices for these transactions range from $66.235 to $67.05, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
Documents
Issuer
CVS HEALTH Corp
CIK 0000064803
Entity typeother
Related Parties
1- filerCIK 0001228603
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 4:15 PM ET
- Size
- 16.9 KB